In the USA, the Food & Drug Authority (FDA) has given permission to Duke University Medical Center to offer cord blood therapy to children with neurological conditions including:
- Autism spectrum disorder
- Cerebral palsy
- Apraxia of speech
- Hypoxia ischemia, cerebral
- Drowning; anoxia
Cerebral palsy affects
1 in 400 children
1 in 100 people have a form of autism
Cells4Life has already provided customer samples to Duke as part of a series of clinical trials over the past couple of years. The FDA approval to allow expanded access to treatment means more families with a child affected by a neurological disorder will be able to travel to Duke University for therapy.
The latest clinical trial NCT03327467 requires participants to have access to cord blood unit in a private bank. This can be their own cord stem cells, or those belonging to a sibling. The unique properties of cells found in the umbilical cord mean for sibling therapy only a partial match is required.
There is a 75% chance that siblings will be a partial match
Just last week, we have released a further two samples to Duke for the treatment for two little boys with Cerebral Palsy. We wish them and their families the very best of luck for the treatment.